Clofazimine Inhibits Human Kv1.3 Potassium Channel by Perturbing Calcium Oscillation in T Lymphocytes
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The Kv1.3 potassium channel plays an essential role in effector memory T cells and has been implicated in several important autoimmune diseases including multiple sclerosis, psoriasis and type 1 diabetes. A number of potent small molecule inhibitors of Kv1.3 channel have been reported, some of which were found to be effective in various animal models of autoimmune diseases. We report herein the identification of clofazimine, a known anti-mycobacterial drug, as a novel inhibitor of human Kv1.3. Clofazimine was initially identified as an inhibitor of intracellular T cell receptor-mediated signaling leading to the transcriptional activation of human interleukin-2 gene in T cells from a screen of the Johns Hopkins Drug Library. A systematic mechanistic deconvolution revealed that clofazimine selectively blocked the Kv1.3 channel activity, perturbing the oscillation frequency of the calcium-release activated calcium channel, which in turn led to the inhibition of the calcineurin-NFAT signaling pathway. These effects of clofazimine provide the first line of experimental evidence in support of a causal relationship between Kv1.3 and calcium oscillation in human T cells. Furthermore, clofazimine was found to be effective in blocking human T cell-mediated skin graft rejection in an animal model in vivo. Together, these results suggest that clofazimine is a promising immunomodulatory drug candidate for treating a variety of autoimmune disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116 · cited 1×
“The selective inhibitory effects of clofazimine on both NFAT and NF-kB over AP-1 suggested that it is likely to affect the activation of their common upstream regulator, calcineurin [1,3,4].”
BackgroundSelf-citationInhibition of Angiogenesis by the Antifungal Drug Itraconazole
Chong, C. R., Xu, J., Lu, J., Bhat, S., Sullivan, D. J., & Liu, J. O. (2007) · ACS Chemical Biology · doi:10.1021/cb600362d · Cited by 210 · cited 1×
“An early version of the library has been described [24].”
BackgroundSelf-citation
Cited by
Voltage-gated potassium channels as therapeutic targets
Wulff, H., Castle, N. A., & Pardo, L. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2983 · Cited by 799
Molecular Basis of Calcium Signaling in Lymphocytes: STIM and ORAI
Hogan, P. G., Lewis, R. S., & Rao, A. (2010) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132550 · Cited by 760
The functional network of ion channels in T lymphocytes
Cahalan, M. D., & Chandy, K. G. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00816.x · Cited by 599
Clofazimine: current status and future prospects
Cholo, M. C., Steel, H. C., Fourie, P. B., Germishuizen, W. A., & Anderson, R. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr444 · Cited by 351
Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone Oxidoreductase
Yano, T., Kassovska-Bratinova, S., Teh, J. S., Winkler, J., Sullivan, K., Isaacs, A., Schechter, N. M., & Rubin, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.200501 · Cited by 346
Metadata
- Authors
- Ren, Y. R., Pan, F., Parvez, S., Fleig, A., Chong, C. R., Xu, J., Dang, Y., Zhang, J., Jiang, H., Penner, R., & Liu, J. O.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-23
- Volume
- 3
- Issue
- 12
- Pages
- e4009
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2167758548
- Cited by
- 114
- References
- 2
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.